SEOUL, Korea, JAKARTA, Indonesia, February 22, 2019 — Scientists from Bio Farma, the University of Indonesia, and the International Vaccine Institute (IVI), recently published the results of a phase I clinical trial study of a novel typhoid conjugate vaccine involving Indonesian adults and children, showing that the vaccine was safe and generated potentially protective immune responses.
Typhoid fever, caused by Salmonella typhi, has a high burden globally and causes an estimated number of up to 200,000 deaths annually. Typhoid fever also affects younger children, particularly in resource-limited settings in endemic countries. Typhoid vaccination is an important prevention tool. However, conventional typhoid polysaccharide vaccines (Vi-PS) are not recommended for children under 2 years of age.
Researchers at IVI and Indonesian partners aimed to define the safety and immunogenicity of a new S. typhi Vi-DT conjugate vaccine. The latest study, published recently in the journal PLoS ONE, suggests that the new vaccine is safe and immunogenic in adults and children over 2 years of age, with a single dose inducing strong immune responses regardless of age.
“This study is an important step towards the development of Vi-DT typhoid vaccine that can safeguard the world’s most vulnerable -especially young children, against typhoid fever,” said Dr. Sushant Sahastrabuddhe, Director of the Typhoid Program at IVI.
Dr. Jerome Kim, Director General of IVI said, “This study paves the way for further clinical development of this vaccine, with the ultimate goal of bringing another typhoid conjugate vaccine to the public sector market.”
The study has been conducted jointly by University of Indonesia/Cipto Mangunkusumo Hospital, and Bio Farma in collaboration with IVI, which developed the vaccine and transferred technology to the Indonesian vaccine and antisera manufacturer. A phase II study of this vaccine is currently ongoing in Indonesia.
“We take pride in the successful collaboration with the team from the University of Indonesia/ Cipto Mangunkusumo Hospital and our partners from IVI -resulting in a very positive outcome of this phase I study. This is the first major milestone in our quest to develop a new TCV,” said Dr. Novilia Sjafri Bachtiar, Surveillance & Clinical Trial Head of Division, Bio Farma.
Adriansjah Azhari, Planning & Development Director of Bio Farma said, “Through collaboration with IVI and experts from Universities in Indonesia, we will complete the clinical development program thus contributing yet another novel TCV to the global health market very soon.”
The full article can be accessed at: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0211784&type=printable
The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children, in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research in more than 30 countries throughout Asia, Africa and Latin America on vaccines against diarrheal infections, bacterial meningitis and pneumonia, as well as Japanese encephalitis and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit www.ivi.int
About Bio Farma
Bio Farma, a state-owned and by far the most prominent vaccine and anti-sera manufacturer in Indonesia, has, since its establishment in 1890, played an important role in supporting global health through the provision of vaccines both nationally and globally. As one of a few WHO-prequalified vaccine manufacturers, Bio Farma’s philosophy is: “Dedicate to Improve Quality of Life”. Expanding its product portfolio to other life science products, Bio Farma continues to engage in research and development activities, collaborating with prominent national as well as international partners. For more information: www.biofarma.co.id
Felicia An, Head of Communications, IVI +82 2 8811309 | Felicia.An@ivi.int
Tae Kyung Byun, Senior Manager of Korean Communications, IVI +82 2 8811159 | email@example.com
N. Nurlaela Arief, Corporate Communications Manager, Bio Farma firstname.lastname@example.org